Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

Background: Therapy monitoring of cancer treatment by contrast-enhanced CT (CECT), applying response evaluation criteria in solid tumors criteria version 1. 1 (RECIST 1.1) is less suitable for neuroendocrine tumors (NETs) which, when responding, tend to show stabilization rather than shrinkage. New...

Full description

Bibliographic Details
Main Authors: Olof Pettersson, Katarzyna Fröss-Baron, Joakim Crona, Anders Sundin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
therapy monitoring
neuroendocrine tumor
computed tomography
contrast-enhancement
NET
CT
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00193/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00193/full

Similar Items